DeepMed Research

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer

Not Applicable

Conditions: Colorectal Cancer Stage III
Colorectal Cancer Stage II

Interventions: Procedure: Chemotherapy time

First Posted Date: 2021-11-23

Last Posted Date: 2021-11-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05131243

Effects of Mobile Medicine on Cancer Patients

Not Applicable

Conditions: Cancer Pain

Interventions: Behavioral: mini program
Behavioral: conventional pharmaceutical care

First Posted Date: 2021-09-20

Last Posted Date: 2021-09-21

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT05049811

Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer

Phase 3

Conditions: Surgery

Interventions: Procedure: conventional laparoscopic surgery
Procedure: single-incision plus one-port laparoscopic surgery

First Posted Date: 2021-09-05

Last Posted Date: 2021-10-11

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT05035446

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Phase 1

Conditions: Advanced Triple Negative Breast Cancer

Interventions: Drug: Apatinib Mesylate
Drug: Albumin-Bound Paclitaxel

First Posted Date: 2021-08-25

Last Posted Date: 2021-08-25

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05019690

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Neoplasms
Esophageal Squamous Cell Carcinoma

Interventions: Drug: Albumin-Bound Paclitaxel
Drug: PD-1 inhibitor
Drug: Cisplatin
Radiation: Radiation

First Posted Date: 2021-08-16

Last Posted Date: 2021-12-21

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 92

Registration Number: NCT05007145

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
the Second Hospital of Longyan, Longyan, Fujian, China
🇨🇳
the First Hospital of Putian City, Putian, Fujian, China

and more 3 locations

Study of FMT Combined With Nivolumab in Gastric Cancer

Not Applicable

Withdrawn

Conditions: Esophagogastric Junction Adenocarcinoma
Esophagus Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: XBI-302 + Nivolumab

First Posted Date: 2021-08-11

Last Posted Date: 2021-10-27

Lead Sponsor: Fujian Cancer Hospital

Registration Number: NCT05001360

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Surufatinib(HMPL-012)

First Posted Date: 2021-07-09

Last Posted Date: 2021-07-09

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 14

Registration Number: NCT04955886

Locations: 🇨🇳
Affiliated Cancer Hospital of Sun Yat-sen University, Guangdong, China
🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China

Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain

Not Applicable

Conditions: Cancer Pain

Interventions: Other: mini program
Other: conventional pharmaceutical care

First Posted Date: 2021-04-14

Last Posted Date: 2021-04-14

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT04844645

IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

Phase 3

Completed

Conditions: Cancer Pain

Interventions: Drug: Hydromorphone Hydrochloride Injection
Drug: Morphine Sulfate Sustained-release Tablets

First Posted Date: 2021-03-08

Last Posted Date: 2025-05-22

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 1372

Registration Number: NCT04785768

Locations: 🇨🇳
China, Fujian, Fuzhou, Fujian, China

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Phase 2

Conditions: Advanced Colorectal Cancer

Interventions: Drug: Surufatinib

First Posted Date: 2021-02-21

Last Posted Date: 2021-11-04

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 10

Registration Number: NCT04764006

Locations: 🇨🇳
China, Fujian, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy